Roche has opened a new research facility for the Institute of Human Biology (IHB) in Basel, Switzerland.
The building will have a total floor area of 23,000sqm over eight floors, and accommodate up to 250 IHB researchers.
Roche is currently investing 1.5bn euros in the site development. The company has invested around 7.6bn euros in its Swiss sites since 2016, with a total investment in the country of around 44.6bn euros between 2016 and 2025.
Thomas Schinecker, CEO of the Roche Group, said: “The inauguration of the Institute of Human Biology reinforces our commitment to Switzerland as a global innovation hub, where Roche invests [around 3.8bn euros] in research each year.
“By combining human organoid models with artificial intelligence, IHB has the potential to change how we discover and develop new medicines – making research and development more predictive and more efficient.”
Focused on replicating human disease biology, IHB brings together diverse expertise across multidisciplinary projects. Included in the design are modular laboratories to encourage sustainable growth and foster interdisciplinary exchange, and a unique colour concept developed by Swiss artist Rémy Zaugg designed to create a collaborative working environment.
Azad Bonni, Global Head and Director of the IHB, said: “Modern medicine requires sophisticated technologies. By pioneering human model systems and better understanding human disease, we will move beyond the limitations of traditional research to predict if and how new treatments will work in people.
“This new research facility allows our scientists to make and translate discoveries at the intersection of fundamental and industry sciences, changing how we understand and tackle human disease.”
Originally constructed in 2000, the building’s renovation was completed in Q4 of 2025, with an opening ceremony held in March 2026.